Pentracor is a medical device company that has developed a breakthrough innovation for the treatment of acute myocardial infarction. Our first product on the German market is PentraSorb® CRP and has attracted much attention since the completion of a landmark clinical trial. Pentracor has a research and development pipeline in several therapeutic areas based on our unique expertise in immunology.
In heart attack and stroke, the C-reactive protein (CRP) leads to an increase of the primary damage. Further, the severity of rheumatic diseases is often determined by the amount of CRP.
The CRP adsorber (PentraSorb® CRP) is CE-marked. The corresponding Quality management system certificate according to EN ISO 13485 and the EC Certificate of Conformity in accordance with Directive 93/42/EEC are available.
Our Flyer summarizes the most important information about the PentraSorb® CRP.
Since November 2014 Pentracor GmbH is responsible and certified for the production and distribution of CRP adsorbers according to EN ISO 13485. The PentraSorb® CRP is an adsorber for the selective depletion of C-reactive protein (CRP).
Promising treatment success in patients with severe COVID-19 courses
Hennigsdorf, 21.04.2021 – Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved further promising treatment successes with its CE-certified and patent-protected medical product PentraSorb® CRP in patients with severe COVID-19 courses. For example, the Havelhöhe Community Hospital in Berlin has been using Pentracor's new therapeutic extracorporeal treatment method for severely ill COVID-19 patients for several weeks and has already achieved a significant improvement in the patients' clinical condition after a short period of time.
CRP apheresis at the Klinikum Havelhöhe shown in the rbb Abendschau
17.04.2021
COVID-19 patients are treated with CRP apheresis at the Klinikum Havelhöhe. This was featured in the rbb Abendschau.
Clinical trial CRP apheresis after myocardial infarction published
11.03.2021
Results of the first clinical trial of CRP apheresis after acute myocardial infarction (CAMI1) were published in the cardiology journal Frontiers in Cardiovascular Medicine.
"CRP apheresis as anti-inflammatory therapy for acute myocardial infarction: results from the CAMI-1 trial."
The article describes that C-reactive protein substantially triggers myocardial damage after myocardial infarction.
Review on the pathomechanism of CRP published
10.02.2021
"C-reactive protein triggers cell death in ischemic cells":
In the Research Topic "Diagnostic and Therapeutic Applications of Pentraxin and Pentraxin-Associated Proteins" of the journal Frontiers in Immunology, a review on the pathomechanism of CRP in organ-damaging inflammation was published.
World's only CRP blood wash therapy now also successful for COVID-19
Hennigsdorf, January 27, 2021 - The medical technology company Pentracor GmbH, headquartered in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has successfully treated a patient suffering from COVID-19 caused by the Corona virus with its CE-certified and patent-protected medical product PentraSorb® CRP. The company has thus created another important option for action in the fight against the often fatal effects of the pandemic.
Report about COVID-19 patient, who was successfully treated with the PentraSorb®
20.01.2021
The Märkische Oderzeitung reported about a recently successfully treated COVID-19 patient. The patient was treated 4 times with CRP apheresis and is recovering rapidly from the disease. The article describes that the therapy most likely saved the patient from intensive care medical treatment.
